Centiva Capital, LP Kodiak Sciences Inc. Transaction History

Centiva Capital, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$77.2 - $126.54 $655,042 - $1.07 Million	-8,485 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$110.45 - $164.47 $646,242 - $962,313	5,851 Added 222.13%	8,485 $962,000
Q4 2020 Feb 16, 2021	SELL	$60.78 - $154.03 $182,461 - $462,398	-3,002 Reduced 53.26%	2,634 $387,000
Q3 2020 Nov 16, 2020	SELL	$45.05 - $59.27 $513,164 - $675,144	-11,391 Reduced 66.9%	5,636 $334,000
Q2 2020 Aug 14, 2020	BUY	$42.74 - $66.25 $727,733 - $1.13 Million	17,027 New	17,027 $922,000

104

39.8M

7.6K

3.5K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $138M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.